RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.